Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Migraine: preventive treatment.

S D Silberstein1, P J Goadsby

  • 1Jefferson Headache Center, and Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA. Stephen.Silberstein@mail.tju.ed

Cephalalgia : an International Journal of Headache
|September 17, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The evolving landscape of primary headache therapy.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same author

Same-Day Bilateral Decubitus CT Myelography for Detecting CSF-Venous Fistulas in Spontaneous Intracranial Hypotension.

AJNR. American journal of neuroradiology·2022
Same author

Visual snow syndrome: is it normal or a disorder - and what to do with patients?

European journal of neurology·2020
Same author

Visual snow syndrome: a comparison between an Italian and British population.

European journal of neurology·2020
Same author

Response to 'Do different treatment strategies of galcanezumab have similar effect on migraine?'

European journal of neurology·2020
Same author

Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials.

European journal of neurology·2019
Same journal

Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project).

Cephalalgia : an international journal of headache·2026
Same journal

Cerebrovascular risk with calcitonin gene-related peptide monoclonal antibodies versus onabotulinumtoxinA in patients with migraine: A real-world pharmacoepidemiologic study in the National Institutes of Health All of Us Research Program.

Cephalalgia : an international journal of headache·2026
Same journal

Burning mouth syndrome and oral dysaesthetic/perceptual symptoms: Toward clinically actionable boundaries.

Cephalalgia : an international journal of headache·2026
Same journal

Effectiveness and clinical predictors of rimegepant for acute vertigo in vestibular migraine: A real-world cohort study.

Cephalalgia : an international journal of headache·2026
Same journal

Efficacy of digital therapeutic sinCephalea for personalised nutrition versus control for migraine prevention: A 12-week open-label randomised clinical trial.

Cephalalgia : an international journal of headache·2026
Same journal

SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study).

Cephalalgia : an international journal of headache·2026
See all related articles

Migraine prevention strategies are crucial for managing this common headache disorder. Effective treatment involves selecting appropriate preventive therapies based on individual patient needs and drug efficacy, while considering potential side effects and comorbidities.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Migraine is a prevalent episodic headache disorder impacting daily life.
  • Comprehensive treatment plans integrate acute pain relief and long-term preventive strategies.

Purpose of the Study:

  • To outline criteria for initiating migraine preventive therapy.
  • To guide the selection of appropriate preventive medications based on efficacy and patient factors.

Main Methods:

  • Review of clinical guidelines and evidence for migraine preventive treatments.
  • Consideration of factors such as attack frequency, impact on daily routines, medication history, and patient preferences.
  • Evaluation of drug efficacy, side effect profiles, and potential drug interactions.

Main Results:

Related Experiment Videos

  • Preventive therapy is indicated when acute treatments are insufficient, contraindicated, or lead to medication overuse.
  • Key factors for drug selection include proven efficacy, patient-specific profiles, side effects, and comorbidities.
  • High-efficacy options with mild-to-moderate adverse events include beta-blockers, amitriptyline, and divalproex.
  • Other options with varying efficacy and adverse event profiles include SSRIs, calcium channel antagonists, gabapentin, topiramate, riboflavin, and NSAIDs.

Conclusions:

  • Personalized preventive treatment plans are essential for effective migraine management.
  • Careful consideration of drug properties and patient characteristics optimizes therapeutic outcomes.
  • Ongoing re-evaluation and patient involvement are critical for successful long-term migraine control.